EFG
DNA icon

Ethos Financial Group’s Ginkgo Bioworks DNA Stock Holding History

Ethos Financial Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,800
Closed -$104K – 307
2024
Q2 		$104K Buy
7,800
+7,350
+1,633% +$219K 0.02% 276
2024
Q1 		$21K Buy
+450
New +$23.3K ﹤0.01% 278
2023
Q4 		– Sell
-1,548
Closed -$112K – 276
2023
Q3 		$112K Sell
1,548
-3,084
-67% -$247K 0.03% 175
2023
Q2 		$246K Hold
4,632
– – 0.08% 115
2023
Q1 		$246K Sell
4,632
-8
-0.2% -$507 0.08% 138
2022
Q4 		$314K Buy
+4,640
New +$427K 0.11% 100

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ethos Financial Group's DNA Position: Q3 2024 in Review

Ethos Financial Group sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 7,800 shares — an estimated $104K sold.

Ethos Financial Group first reported a position in DNA in Q4 2022 and held it in 6 quarters. The position peaked at $314K in Q4 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Ethos Financial Group reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Ethos Financial Group sold 7,800 Ginkgo Bioworks shares in Q3 2024, an estimated $104K.
  • Ethos Financial Group first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 6 quarters.
  • Ethos Financial Group's Ginkgo Bioworks position peaked at $314K in Q4 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Ethos Financial Group's 13F filing for Q3 2024, filed 7 Nov 2024.